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Abstract: Aortic valve interstitial cells (VICs) constitute a heterogeneous population involved 
in the maintenance of unique valvular architecture, ensuring proper hemodynamic function but 
also engaged in valve degeneration. Recently, cells similar to telocytes/interstitial Cajal-like cells 
described in various organs were found in heart valves. The aim of this study was to examine the 
density, distribution, and spatial organization of a VIC subset co-expressing CD34 and PDGFRa 
in normal aortic valves and to investigate if these cells are associated with the occurrence of early 
signs of valve calcific remodeling. We examined 28 human aortic valves obtained upon autopsy. 
General valve morphology and the early signs of degeneration were assessed histochemically. 
The studied VICs were identified by immunofluorescence (CD34, PDGFRa, vimentin), and their 
number in standardized parts and layers of the valves was evaluated. In order to show the complex 
three-dimensional structure of CD34+/PDGFRa+ VICs, whole-mount specimens were imaged by 
confocal microscopy, and subsequently rendered using the Imaris (Bitplane AG, Zürich, Switzerland) 
software. CD34+/PDGFRa+ VICs were found in all examined valves, showing significant differences 
in the number, distribution within valve tissue, spatial organization, and morphology (spherical/oval 
without projections; numerous short projections; long, branching, occasionally moniliform projections). 
Such a complex morphology was associated with the younger age of the subjects, and these VICs were 
more frequent in the spongiosa layer of the valve. Both the number and percentage of CD34+/PDGFRa+ 
VICs were inversely correlated with the age of the subjects. Valves with histochemical signs of 
early calcification contained a lower number of CD34+/PDGFRa+ cells. They were less numerous 
in proximal parts of the cusps, i.e., areas prone to calcification. The results suggest that normal 
aortic valves contain a subpopulation of CD34+/PDGFRa+ VICs, which might be involved in the 
maintenance of local microenvironment resisting to pathologic remodeling. Their reduced number in 
older age could limit the self-regenerative properties of the valve stroma.
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1. Introduction
Aortic valve lesion, known as calcific aortic valve disease (CAVD) is the most widespread 
pathology of the heart valves. It is associated with intravalvular inflammation, calcium and lipid 
deposition, and overproduction of the aberrant extracellular matrix, resulting in valve sclerosis and 
consequently, stenosis [1,2]. Discrete calcification occurs very early in this pathology, leading with 
time to irreversible, substantial calcific degeneration, and sometimes ossification [1,3- 5]. Theories on 
mechanisms involved in CAVD development have been evolving through the years, leading to the 
currently accepted view, that at the tissue level, this pathology is a process actively regulated by various 
resident and migratory cells (e.g., interstitial or endothelial cells versus inflammatory cells) [1,5,6]. 
Since the mechanism of this process remains unclear, there is still no effective treatment other than 
surgical replacement of the defective valve.
Aortic valve (AV) ensures unidirectional blood flow preventing retrograde flow from the aorta 
into the left ventricle. Anatomically, the aortic valve (AV) is composed of three cusps (leaflets): 
left coronary cusp (LCC), right coronary cusp (RCC), and non-coronary cusp (NCC), attached to the 
fibrous ring, forming as a whole, a crown-like structure [7]. Each cusp is covered by endothelial cells 
and composed of three connective tissue layers: (i) highly collagenous fibrosa, facing aorta lumen, 
(ii) glycosaminoglycans/proteoglycans-rich spongiosa lying at the middle level, and (iii) elastin-rich 
ventricularis, facing the ventricular cavity. Under normal conditions, cusps are thin, pliable, avascular, 
autonomically innervated structures coated by valve endothelial cells (VECs), and populated mainly by 
valve interstitial cells (VICs) [8,9]. VICs are located in each layer of the aortic valve [10] and synthesize 
extracellular matrix components, including collagen, elastin, and glycosaminoglycans, hence they 
functionally resemble fibroblasts [9].
Valvular cells and their reciprocal interactions are essential players in CAVD [11]. The mammalian 
heart built of cardiomyocytes also contains a large population of non-myocyte cells (e.g., interstitial 
cells, endothelial cells) [12,13]. Recently, VICs have been discussed in the literature as important players 
in the degeneration of the heart valves, participating in the pathogenesis of CAVD [11,14- 16]. These 
double-faced cells seem to be crucial in homeostasis regulation but, on the other hand, are responsible for 
aortic valve fibrosis and osteogenic degeneration, which is associated with activation of developmental 
transcriptional regulatory pathways [17- 20]. Of note is that aortic valve cells populating particular 
cusps may have a distinct embryological origin, since LCC and RCC arise from the conotruncal 
(superior and inferior septal) cushions, while NCC arises from the posterior intercalated cushion of the 
outflow tract [10,21]. This may explain important functional differences in VICs isolated from different 
cusps [22].
According to the literature, VICs constitute a heterogenous population and can be divided into 
several phenotypes, which are engaged in physiological and pathological processes. Liu et al. [16] 
distinguished five phenotypes in the VICs family: embryonic progenitor endothelial/mesenchymal 
cells, quiescent VICs (qVICs), activated VICs (aVICs), progenitor VICs (pVICs), and osteoblastic VICs 
(obVICs). The cytological features of activated VICs (aVICs) correspond to those of myofibroblasts, 
described in valves by numerous authors and reported to play an important role in valve fibrosis 
contributing to degenerative processes such as valve sclerosis and atherosclerosis [23]. However, 
Combs et al. claimed that neither the commitment of VICs to the separate, fixed lineages nor the 
specific origin of VIC in distinct valve compartments have been unequivocally defined and proved [24].
It has been found that in the heart, there exists a population of interstitial cells morphologically 
similar to interstitial Cajal-like cells/telocytes (TCs) [25- 31]. Cardiac interstitial Cajal-like cells have 
a mesenchymal origin, make numerous contacts with other types of surrounding cells, as well as 
with each other. They are involved in the 3D-tissue organization and fibrosis, tissue remodeling, and
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repair [32- 36], as well as, indirectly, in the organization of the extracellular matrix, structural support, 
creation of microenvironments, intercellular communication, neurotransmission, immunomodulation 
and immunosurveillance, inhibition of apoptosis, and control, regulation and source of other cell 
types [37].
Recently it has been suggested that also in heart valves, there exists a population of cells expressing 
both hematopoietic and mesenchymal stem cell markers akin to interstitial Cajal-like cells/telocytes 
(TCs), which could constitute a special subpopulation of the VICs [35].
The aim of this study was to examine the presence, distribution, and morphology of cells 
co-expressing CD34 and PDGFRa in human aortic valves, and to investigate if the presence of these 
cells is associated with the occurrence of the early signs of valve calcific degeneration.
2. Results
2.1. CD34+/PDGFRa+ Cells Constitute Substantial Subpopulation of VICs
All examined valves were pliable and macroscopically normal. Histological examination revealed 
their well-preserved, three-layered structure (Figure 1). Cells double positive for CD34 and PDGFRa 
(Figure 2) were found in the fibrosa and spongiosa layers of all the examined valves and their density 
in the individual valves ranged from 20 to 290/mm2, i.e., from 5% to 63% of the whole VICs population. 
As the other VICs, they were also positive for vimentin.
A B
- I 1 —
Figure 1. Normal morphology of the aortic valve. (A) Paramedian longitudinal section of a valve cusp 
spanning its basal-B, proximal-P, and distal-D parts. Higher magnification of the basal cusp part 
(inset) shows typical three-layered architecture: F-fibrosa, S-spongiosa, V-ventricularis. Hematoxylin 
and eosin staining. Scale bar = 2 mm. (B) Stereomicroscope image showing whole-mount specimen of 
the medial part of the bisected cusp with demarcation of its three parts (B, P, D) as in (A).
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Figure 2. Identification, variability, and spatial organization of CD34/PDGFRa double positive cells in 
the human aortic valve. (A) Laser scanning confocal microscopy image showing co-localization of CD34 
(red) and PDGFRa (green) in selected cells. Grayscale images show signals from the red, green, and blue 
channels, respectively. (B,C). Reconstruction images of two morphologically different CD34+/PDGFRa+ 
cells based on the whole-mount valve specimens imaged by confocal microscopy and subsequently 
rendered using the Imaris (Bitplane AG, Zürich, Switzerland) software. (D) Differences in the spatial 
organization of CD34+/PDGFRa+ cells in fibrosa-F, and spongiosa-S. Whole-mount specimen. Imaged 
cusp area is presented graphically. (E) High magnification image showing three-dimentional network of 
CD34+/PDGFRa+ cells in spongiosa. Note the moniliform projections (one is arrowed). Whole-mount 
specimen. Scale bars: 15 qm (A), 10 qm (B,C), 50 qm (D), 20 qm (E).
2.2. Morphology and Spatial Organization o f CD34+/PDGFRa+ Cells Is Regionally Different
The whole-mount specimens, z-stack imaged by confocal microscopy, allowed to visualize diverse 
morphology of CD34+/PDGFRa+ cells: from oval, without any projections, to much more complex 
forms with numerous branched, slender, frequently moniliform projections tens to hundreds of 
micrometers long (Figure 2) arising from relatively small cell bodies. Moreover, these cells were 
characterized by different spatial distributions in the valve layers. In fibrosa, they were mostly parallel 
to the collagen fibers, highly elongated or spherical, while in spongiosa, they were organized into 
three-dimensional net-like structure (Figure 2D).
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2.3. The Abundance and Morphology o f CD34+/PDGFRa+ Cells Are Associated with Age
On the basis of the prevalence of morphological forms of CD34+/PDGFRa+ VICs, we distinguished 
three groups among all examined aortic valves. Group 1 (n = 5; mean age 35 ± 6.03)—cells with 
numerous and long projections, group I2 (n = 8; mean age 49 ± 4.42)—cells with short unbranched 
projections, group 3 (n = 15; mean age 56.5 ± 3.01)—cells with virtually no projections (Figure 3A-C).
Figure 3. Changes in morphology and abundance of CD34+/PDGFRa+ cells related to age. 
(A-C) Confocal microscopy images of CD34+/PDGFRa+ cells representative for the examined valve 
groups: 1, 2, and 3, respectively. Note, gradual reduction of cell projections comparing Group 1 to 
Groups 2, and 3. Scale bars = 20 qm. (D) Graph showing the mean age of the valve donors in three 
groups of aortic valves: Group 1 valves were from significantly younger subjects than Group 3 valves 
(** p < 0.01; values presented as the means ± SD). Graphs (E,F) demonstrate a significant decrease in 
the CD34+/PDGFRa+ cell percentage and number, respectively, with age.
Our results showed that valves with morphologically most complex CD34+/PDGFRa+ VICs 
(group I) were derived from significantly younger individuals (Figure 3D). Moreover, both the number 
and percentage of CD34+/PDGFRa+ VICs were inversely correlated with the age of the subjects 
(R = -0.66; p < 0.001 and r = -0.5; p < 0.01 for number and percentage, respectively) Figure 3E,F.
2.4. Early Calcification Is Associated with Decrease in the Number and Proportion o f CD34+/PDGFRa+ Cells
CD34+/PDGFRa+ VICs were significantly less numerous in the basal and proximal parts of 
the cusps (99.26 ± 13.58; 90.74 ± 11.02; 140 ± 18.78 cells/mm2 for basal, proximal, and distal parts, 
respectively), i.e., areas prone to developing degenerative changes, especially calcifications (Figure 4C). 
We compared the cellular architecture of the aortic valves with and without signs of calcification. 
Early degenerative lesions (foci of calcifications in the basal and proximal parts of fibrosa), not affecting 
the general valve morphology (Figure 4A,B) were found in 11 cases (39%). These valves were from older
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individuals (mean age 61.27 ± 5.75 years vs. 43.53 ± 13.94 years for calcified and non-calcified valves; 
p < 0.001). Valves with calcifications contained significantly lower numbers of CD34+/PDGFRa+ cells in 
both, fibrosa (6.67 [4.75-9.00] vs. 13.25 [7.37-19.75] for calcified and non-calcified, respectively p < 0.05) 
(Figure 4D) and spongiosa (7.00 [4.33-13.50] vs. 16.00 [6.00-19.21] for calcified and non-calcified, 
respectively; not significant). A substantial reduction of CD34+/PDGFRa+ VICs population correlated 
with age (R = -0.77; p = 0.005 for percentage; R = -0.66; p = 0.03 for density) was seen only in 
the basal/proximal fibrosa of the valves with calcifications as compared with the valves without 
calcifications in these areas (Figure 4E).
Figure 4. Association of CD34+/PDGFRa+ cells with initial calcification in aortic valves. (A) Micrograph 
of Alizarin red-stained non-stenotic aortic valve with signs of calcification (red) in the basal part of 
the cusp. As seen at higher magnification (B) calcifications are limited to the fibrosa layer (F-fibrosa, 
S-spongiosa). Scale bars: 2 mm (A), 1.5 mm (B). (C) Density of CD34+/PDGFRa+ VICs in three parts 
of the valve: they are significantly more numerous in the distal parts (not affected by calcification) of 
the cusps (** p < 0.01; values presented as the means ± SD). (D) Graph showing that CD34+/PDGFRa+ 
cells in fibrosa are significantly less numerous in the calcified valves compared with non-calcified 
ones. Box-and-whisker plot. Whiskers indicate 1.5 x IQR (interquartile range) beyond the box (Tukey 
style). Dot indicates an outlier (* p < 0.05). In spongiosa, the difference was not significant (not shown).
(E) Graphs demonstrating a substantial age-related reduction of CD34+/PDGFRa+ cell population: 
cell percentage (top) and density (bottom) in the basal/proximal fibrosa of the valves with calcifications 
in these areas (left panel) versus insignificant changes in the same valve areas of the valves free from 
calcifications (right panel).
3. Discussion
Interstitial cells constitute a significant cellular component of the human heart [12]. Their role
in valves is essential for maintaining local homeostasis and pathologic remodeling. Demonstration
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of interstitial Cajal-like cells (telocytes) in various organs has attracted a lot of attention from the 
scientific community in the last decade. Irrespectively of telocyte diversity, CD34/PDGFRa seems 
to be a valuable marker used for their immunohistochemical identification in various localizations, 
including heart tissues [29,38]. In 2014, Yang et al. [35] were the first to demonstrate Cajal-like/telocyte 
cells different from the "traditional" VICs in human aortic valves. They were immunopositive for 
CD34/vimentin, CD34/c-kit, and CD34/PDGFRp. In the following year, Zhou et al. [34] described 
CD34/PDGFRa positive cells in the valves of rats and humans.
Data on the abundance of the Cajal-like cells/telocytes in different cusp regions are scanty and 
difficult for comparison. The matter is complicated by the fact that their distribution in particular 
organs is not uniform [28]. Anyway, it could be supposed that Cajal-like cells/telocytes vary in different 
organs, usually constituting a few percent of the total cell number [39,40] .
We found that CD34+/PDGFRa+ cells make up from 5% to 63% of the whole VICs population in 
the human aortic valves. In vitro studies on rat cardiac interstitial cells showed that CD34+/PDGFRa+ 
cells constituted 29-41% of the entire cell population [34]. In contrast, Popescu et al. [12] estimated the 
percentage of telocytes in the human cardiac interstitial tissue to be only 1%. Interestingly, they found 
a decrease in the number of these cells in aging hearts, which is consistent with the inverse correlation 
between aortic valve CD34+/PDGFRa+ cell number and age found in the present study.
The microarchitecture of the normal aortic valve is surprisingly complex, ensuring its strength and 
durability, but undergoing substantial disorganization in pathologic conditions [41,42]. The differences 
between valve layers include not only their chemical composition but also the directional arrangement 
of their components. Collagen fibers, being the principal component of the fibrosa mostly show a 
circumferential orientation in each cusp, while the elastic elements in the ventricularis generally are 
directed radially [43]. In spongiosa, joining the layers mentioned above, the predominant extracellular 
matrix (ECM) elements (proteoglycans and glycoproteins) form a fine, molecular network-like structure.
We found CD34+/PDGFRa+ VICs in the fibrosa and spongiosa layers. Analysis of the whole-mount 
specimens allowed us to visualize the different spatial organization of these VICs, reflecting the 
organization of ECM in those layers—highly elongated double-positive VICs, showing a parallel 
arrangement along the collagen fibers in fibrosa and the cellular meshwork in spongiosa.
Several lines of evidence suggest regional heterogeneity of both VICs and VECs in heart 
valves [44- 46]. In this study, we observed that the density of CD34+/PDGFRa+ VICs is significantly 
lower in more proximal parts of the cusps compared to more distal ones. It is known that the 
proximal part of the cusp is more prone to develop degenerative changes; local calcifications 
and focal accumulations of inflammatory cells [6]. Furthermore, a significantly lower number 
of CD34+/PDGFRa+ VICs was found in the fibrosa of the valves with initial calcifications, i.e., in the 
layer, mostly as first affected by calcification.
It is known that valve structure evolves over the lifetime [47,48]. However, it is difficult to 
determine which valvular changes reflect natural adaptation to the hemodynamic conditions and 
which are merely degenerative. A decrease in the overall valve cellularity with age could be regarded 
as a naturally occurring phenomenon since it is known that valve aging is associated with decrease 
in valve cellularity [49]. Of note is that our results show not only a decrease in the number of 
CD34+/PDGFRa+ cells but also in their proportion to other VICs. Since this imbalance was particularly 
evident in initially calcified valves, it might suggest that CD34+/PDGFRa+ VICs are either very 
sensitive for calcific matrix remodeling or are important for maintaining local milieu resistant to 
calcification. It is also possible that both hypotheses are reasonable. Moreover, it is well recognized that 
dying VICs facilitate calcification [50- 52]. It cannot be excluded that the increased rate of cell death 
(including CD34+/PDGFRa+ cells) in valve areas with lower cellularity creates per se local milieu 
prone to calcification.
An unexpected finding in this study was the morphological diversity of CD34+/PDGFRa+ VICs. 
Only a fraction of this cell population revealed typical telocyte morphology with long, moniliform 
projections. The other CD34+/PDGFRa+ VICs either had shorter, often unbranched processes or
Int. J. Mol. Sci. 2020, 21, 6330 8 of 14
even almost no projections. This brings the question of whether such cells can be classified as an 
unusual subset of telocytes. It must be clearly stated that our study based on immunofluorescence and 
confocal microscopy of the whole-mount specimens and valve sections does not allow to answer this 
question. However, Richter et al. [53] described telocytes with extremely short processes in failing 
human heart tissue morphologically resembling our Group 3 CD34+/PDGFRa+ VICs. The authors 
attributed the significant reduction in the number of telocytes and the reduction or even absence 
of their processes (telopodes) to alterations of the ECM, especially to fibrosis. Therefore, it seems 
probable that all CD34+/PDGFRa+ VICs belong to the telocyte family and the gradual reduction of 
their projections with age found in the present study is associated with age-dependent changes of the 
valve interstitial microenvironment.
Different shapes of the body and projections of CD34+/PDGFRa+ VICs might be a result of aging 
accompanied by degenerative processes. For instance, telocytes described previously in the human 
heart are highly sensitive to hypoxia. They show severe ultrastructural alterations such as cytoplasmic 
vacuolization, absence of the telocytes labyrinthine components, as well as shrinkage and shortening of 
the telopodes (extensions) [53- 55]. The milieu prone to hypoxia occurring in valves during age-related 
fibrocalcific remodeling might trigger a simplification of the form and reduction of the number of 
CD34+/PDGFRa+ VICs.
It remains unclear whether the existence of different morphological forms of CD34+/PDGFRa+ 
VICs in the human aortic valves reflects some pathological state, but the prevalence of their particular 
forms in certain age groups is a fact. Moreover, the number and percentage of CD34+/PDGFRa+ VICs 
inversely correlated with age. Thus, our older patients had a lower number of CD34+/PDGFRa+ 
VICs, among which simplified, "rudimentary" forms with significantly reduced projections were 
predominant. On the contrary, the younger population had a higher number and percentage of the 
cells with long-branched cellular projections. In our opinion, the population of CD34+/PDGFRa+ VICs 
could represent a "private reserve" of abilities to save a right balance in the local homeostasis. Besides, 
the same trend was observed when we compared calcified and non-calcified aortic valves—calcification 
was accompanied by decline of CD34+/PDGFRa+ VICs density in the tissue. It remains in agreement 
with results of Nomura et al. [56] who showed that a loss of the CD34 antigen positivity in VICs 
facilitated valvular ECM calcification.
Since our study is retrospective and comprises a relatively low number of cases, we cannot 
definitively determine if or which CD34+/PDGFRa+ VICs changes precede or follow the 
calcific remodeling.
According to the VIC paradigm, the main cells in the valve stroma are responsible for the 
maintenance of valve ECM, and the balance between their quiescent and activated phenotype is 
fundamental for valve homeostasis [16,57]. Most of them, in normal conditions, are classified as 
quiescent VICs (qVICs). They preserve the natural three-layered, avascular valve morphology 
continuously renewing defective ECM components, in particular collagen, what may cause their 
transient activation (aVICs) by various mechanical (hemodynamic) and biochemical stimuli [58]. 
However, prolonged activation and proliferation of myofibroblast-like activated VICs are associated 
with aberrant remodeling of the valve with its fibrosis, calcification, and occasionally ossification 
driven by VICs with osteogenic potential (obVICs).
It is known that VICs include a subpopulation of progenitor cells (pVICs) comprising resident 
valvular cells and circulating (bone marrow-derived) cells entering valve stroma. The occurrence of 
progenitor cells expressing both endothelial and mesenchymal markers in mature valves supports 
the thesis that in adults, the process of endothelial to mesenchymal transition (EMT), fundamental in 
valvulogenesis also supplements the VICs population [59]. It is not clear if the differences in the origin 
of VICs influence their activity in physiologic and pathologic conditions. Some evidence suggests 
the participation of EMT in the calcific remodeling of the valves. Hjortnaes et al. [57] demonstrated 
that EMT precedes calcification and transition of VECs into osteoblastic-like cells in aortic valves. 
Interestingly, they also found that VICs may suppress EMT and calcification of VECs undergoing EMT.
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Recent studies indicate that PDGFRa positive cells in various localizations may participate in 
either proper tissue regeneration after injury or aberrant, fibrotic remodeling, depending on their 
differentiation status [60,61]. Bearing in mind that CAVD is an age-related pathology affecting mostly 
older subjects, the decreased percentage and number of CD34+/PDGFRa+ VICs in elder individuals as 
well as in valves subjected to initial calcification suggests that this VICs subpopulation is only indirectly 
involved in calcific degeneration.
On the other hand, CD34+/PDGFRa+ VICs with long projections, resembling typical Cajal-like 
cells/telocytes, being more numerous in younger subjects, could be involved in the maintenance 
of intravalvular structural (3-dimensional, layered organization of ECM) organization. Moreover, 
some data suggest that interstitial Cajal-like cells/telocytes in the lungs might be involved in the 
modulation of oxidative stress levels and the inhibition of apoptosis, both being well-established 
factors participating in calcific aortic valve degeneration from its earliest stages [62- 64].
In conclusion, we have demonstrated that normal aortic valves contain a subpopulation of 
VICs co-expressing CD34 and PDGFRa, which might be involved in the maintenance of the local 
microenvironment resistant to pathologic remodeling. Their lower number and reduced processes in 
older age may substantially limit self-regenerative properties of the valve stroma, making it more prone 
to degeneration and calcification. Further studies are required to analyze more data and parameters of 
valve interstitial cells. Nevertheless, the new subpopulation of VICs, double-positive for CD34 and 
PDGFRa, should be taken into account for a better understanding of the pathogenesis of the most 
widespread human heart valve pathology.
4. Materials and Methods
4.1. Subjects
Aortic valve specimens were obtained upon autopsy from 28 subjects (mean age 
50.50 ± 14.33 years)—twenty-two men (79%) and six women (21%), who died accidentally. 
No cardiovascular pathologies were detected upon autopsy. Following a gross inspection under Stemi 
2000C stereomicroscope (Zeiss, Jena, Germany), all cusps were bisected along the line passing from the 
cusp base to its free margin and the left half of each was subjected to the routine histological procedure, 
while the right half was processed as a whole-mount (WM) specimen in order to show the complex 
three-dimensional structure of VICs (Figure 1). To avoid the influence of intercuspal differences [46], 
non-coronary cusps (usually calcified at the earliest) were subjected to quantitative evaluation.
4.2. Ethical Approval
The study was conducted in accordance with the moral, ethical, regulatory and scientific principles 
governing clinical research. All samples were retrieved with the approval of the Jagiellonian University 
Bioethical Committee using procedures that conformed to the Declaration of Helsinki guidelines 
(approval number-1072.6120.103.2018; 20 April 2018).
4.3. Tissue Processing
All tissue samples were fixed for 24 h in 4% buffered paraformaldehyde. For routine histology, 
six qm serial sections were cut and mounted on polylysine-coated slides (Menzel-Glaser; Thermo 
Scientific, Dreieich, Germany). The sections were deparaffinized, rehydrated, and stained either with 
hematoxylin-eosin (HE) to assess general valve morphology or with Alizarin red for detection of 
calcified areas.
4.4. Immunofluorescence
After deparaffinization and rehydration, the slides were preincubated for 40 min with 5% 
normal goat serum (Vector, Burlingame, CA, USA; # S-1000) in PBS containing 0.01% sodium azide, 
0.05% thimerosal, 0.1% bovine serum albumin and 0.5% Triton X-100 to reduce nonspecific binding
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and to increase penetration of the antibodies. Then specimens were incubated at 4 °C either overnight 
or for 1.5 days with gentle rotation in case of whole-mounts in PBS with the normal serum containing 
a primary antibody (or a mixture of primary antibodies) and 0.5% Triton X-100. After five washes 
(10 min each) in PBS, the specimens were incubated for 1.5 h (overnight in case of whole-mounts) at 
room temperature with the secondary antibody (or a mixture of secondary antibodies). Indirect double 
immunofluorescence for identification of VIC, both in sections and whole- mounts were performed 
with mouse anti-human or rabbit anti-human primary antibodies against CD34 (1:50; code: NCL-END; 
Novocastra, Newcastle, UK/Leica Biosystems, Newcastle upon Tyne, UK), PDGFRa (1:100, code: 
ab124392; Abcam, Cambridge, UK) and vimentin (1:100, code: NCL-VIM; Novocastra, Newcastle, 
UK/Leica Biosystems, Newcastle upon Tyne, UK). Secondary antibodies included goat anti-mouse 
Alexa555-conjugated antibody (1:200; code: A-21424; Molecular Probes, Eugene, OR, USA) and goat 
anti-rabbit Alexa488-conjugated antibody (1:200; code: A-11008; Molecular Probes, Eugene, OR, USA). 
Negative controls were performed with the omission of the primary antibodies. Finally, the slides 
were washed in two changes (10 min each) of PBS and coverslipped in fluorescence mounting medium 
containing DAPI (4',6-diamidino-2-phenylindole) for counterstaining of cell nuclei (Sigma, Saint Louis, 
MO, USA).
4.5. Microscopic Examination
Specimens were examined under a scanning confocal microscope (FluoView FV1200, Olympus, 
Tokyo, Japan). The images were collected using the FV10-ASW v.4.2a (Olympus, Tokyo, Japan) 
software. The number of cells in the respective part/layer was counted in 5-10 randomly chosen high 
magnification (400x) fields and recalculated for square millimeters. In order to show the complex 
three-dimensional structure of the immunolabelled VICs, whole-mount valve specimens were z-stack 
imaged by confocal microscopy and subsequently rendered using the Imaris v. 7.7.1 (Bitplane AG, 
Zürich, Switzerland) software. All samples were assessed by two independent observers (each blinded 
to the other) without any knowledge of the clinical parameters to avoid bias.
4.6. Statistical Analysis
The variables were expressed as mean ± SD or median [lower-upper quartile values] depending 
on their type and distribution. The statistical analysis included (in compliance with the specific 
category of collected data) t-Student test (or Mann-Whitney U test) and repeated measures ANOVA 
test followed by the Newman-Keuls post hoc test. Correlations between continuous variables were 
analyzed by the Pearson test. Statistical analyses were performed using the Statgraphics Centurion 
XVI (StatPoint Technologies INC, Warrenton, USA) software. All tests were two-tailed with p < 0.05 
considered statistically significant.
Author Contributions: Conceptualization, G.J.L., A.D. and M.K.H..; methodology, G.J.L., A.D., K.G. and J.A.L.; 
software, M.L. and B.S.; validation, A.D. and E.J.-G.; formal analysis, G.J.L., V.A. and E.J.-G.; investigation, G.J.L., 
A.D., M.L., B.S. and K.W.; resources, A.D., M.L., B.S., K.W. and M.K.H.; data curation, V.A.; writing—original draft 
preparation, G.J.L., A.D., M.L. and V.A.; writing—review and editing, B.S., K.W., E.J.-G., M.K.H., K.G. and J.A.L.; 
visualization, G.J.L., M.L. and K.W.; supervision, K.G. and J.A.L.; project administration, G.J.L. and M.L.; funding 
acquisition, G.J.L. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by statutory grants (K-ZDS-007919 and N41/DBS/000060 to G.J.L.) from the 
Jagiellonian University Medical College.
Acknowledgments: The authors would like to extend special thanks to the late Mariusz Gajda (Department of 
Histology, Jagiellonian University Medical College) for his excellent knowledge and technical support of image 
analysis and to the late Wiesława Klimek-Piotrowska (Department of Anatomy, Jagiellonian University Medical 
College) for her invaluable help in conducting this study.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2020, 21, 6330 11 of 14
References
1. O'Brien, K.D. Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal 
more). Arterioscler. Thromb. Vasc. Biol. 2006,26,1721-1728. [CrossRef] [PubMed]
2. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; 
de Simone, G.; Ford, E.S.; et al. American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation 2011,123, e18-e209. [CrossRef] [PubMed]
3. Mohler, E.R., 3rd; Gannon, F.; Reynolds, C.; Zimmerman, R.; Keane, M.G.; Kaplan, F.S. Bone formation and 
inflammation in cardiac valves. Circulation 2001,103,1522-1528. [CrossRef]
4. Lis, G.J.; Czapla-Masztafiak, J.; Kwiatek, W.M.; Gajda, M.; Jasek, E.; Jasinska, M.; Czubek, U.; Borchert, M.; 
Appel, K.; Nessler, J.; et al. Distribution of selected elements in calcific human aortic valves studied by 
microscopy combined with SR-muXRF: Influence of lipids on progression of calcification. Micron 2014, 67, 
141-148. [CrossRef] [PubMed]
5. Lis, G.J.; Czubek, U.; Jasek-Gajda, E.; Loboda, A.; Dulak, J.; Nessler, J.; Kapelak, B.; Sadowski, J.; Litwin, J.A. 
Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves. Pol. Arch. 
Intern. Med. 2016,126,149-158. [CrossRef]
6. Otto, C.M.; Kuusisto, J.; Reichenbach, D.D.; Gown, A.M.; O'Brien, K.D. Characterization of the early lesion of 
'degenerative' valvular aortic stenosis, histological and immunohistochemical studies. Circulation 1994, 90, 
844-853. [CrossRef]
7. Misfeld, M.; Sievers, H.H. Heart valve macro- and microstructure. Philos. Trans. R. Soc. Lond. B Biol. Sci. 
2007, 362,1421-1436. [CrossRef]
8. Lerman, D.A.; Prasad, S.; Alotti, N. Calcific Aortic Valve Disease: Molecular Mechanisms and Therapeutic 
Approaches. Eur. Cardiol. 2015,1 0 ,108-112. [CrossRef]
9. Leopold, J.A. Cellular mechanisms of aortic valve calcification. Circ. Cardiovasc. Interv. 2012, 5, 605-614. 
[CrossRef]
10. Niaz, T.; Hagler, D.J. Is there a genetic basis to the different morphological subtypes of bicuspid aortic valve? 
Ann. Transl. Med. 2018, 6, S117. [CrossRef]
11. Rutkovskiy, A.; Malashicheva, A.; Sullivan, G.; Bogdanova, M.; Kostareva, A.; Stenslokken, K.O.; Fiane, A.; 
Vaage, J. Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification. 
J. Am. Heart Assoc. 2017, 6, e006339. [CrossRef] [PubMed]
12. Popescu, L.M.; Curici, A.; Wang, E.; Zhang, H.; Hu, S.; Gherghiceanu, M. Telocytes and putative stem cells in 
ageing human heart. J. Cell Mol. Med. 2015,19, 31-45. [CrossRef] [PubMed]
13. Adler, C.P.; Costabel, U. Cell number in human heart in atrophy, hypertrophy, and under the influence of 
cytostatics. Recent Adv. Stud. Cardiac Struct. Metab. 1975, 6, 343-355. [PubMed]
14. Weber, A.; Barth, M.; Selig, J.I.; Raschke, S.; Dakaras, K.; Hof, A.; Hesse, J.; Schrader, J.; Lichtenberg, A.; 
Akhyari, P. Enzymes of the purinergic signaling system exhibit diverse effects on the degeneration of valvular 
interstitial cells in a 3-D microenvironment. FASEB J. 2018, 32, 4356-4369. [CrossRef]
15. Li, C.; Xu, S.; Gotlieb, A.I. The progression of calcific aortic valve disease through injury, cell dysfunction, 
and disruptive biologic and physical force feedback loops. Cardiovasc. Pathol. 2013, 22,1-8. [CrossRef]
16. Liu, A.C.; Joag, V.R.; Gotlieb, A.I. The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating 
Heart Valve Pathobiology. Am. J. Pathol. 2007,171,1407-1418. [CrossRef]
17. Taylor, P.M.; Batten, P.; Brand, N.J.; Thomas, P.; Yacoub, M.H. The cardiac valve interstitial cell. Int. J. Biochem. 
Cell Biol. 2003, 35,113-118. [CrossRef]
18. Wirrig, E.E.; Yutzey, K.E. Conserved transcriptional regulatory mechanisms in aortic valve development and 
disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34,737-741. [CrossRef]
19. Rattazzi, M.; Donato, M.; Bertacco, E.; Millioni, R.; Franchin, C.; Mortarino, C.; Faggin, E.; Nardin, C.; 
Scarpa, R.; Cinetto, F.; et al. l-Arginine prevents inflammatory and pro-calcific differentiation of interstitial 
aortic valve cells. Atherosclerosis 2020,298, 27-35. [CrossRef]
20. Lee, S.H.; Choi, J.H. Involvement of Immune Cell Network in Aortic Valve Stenosis: Communication between 
Valvular Interstitial Cells and Immune Cells. Immune Netw. 2016,16, 26-32. [CrossRef]
21. Martin, P.S.; Kloesel, B.; Norris, R.A.; Lindsay, M.; Milan, D.; Body, S.C. Embryonic Development of the 
Bicuspid Aortic Valve. J. Cardiovasc. Dev. Dis. 2015, 2, 248-272. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 6330 12 of 14
22. Masjedi, S.; Amarnath, A.; Baily, K.M.; Ferdous, Z. Comparison of calcification potential of valvular interstitial 
cells isolated from individual aortic valve cusps. Cardiovasc. Pathol. 2016, 2 5 ,185-194. [CrossRef] [PubMed]
23. Singh, S.; Torzewski, M. Fibroblasts and Their Pathological Functions in the Fibrosis of Aortic Valve Sclerosis 
and Atherosclerosis. Biomolecules 2019, 9, 472. [CrossRef] [PubMed]
24. Combs, M.D.; Yutzey, K.E. Heart valve development: Regulatory networks in development and disease. 
Circ. Res. 2009,105, 408-421. [CrossRef] [PubMed]
25. Radu, B.M.; Banciu, A.; Banciu, D.D.; Radu, M.; Cretoiu, D.; Cretoiu, S.M. Calcium Signaling in Interstitial 
Cells: Focus on Telocytes. Int. J. Mol. Sci. 2017,18, 397. [CrossRef]
26. Kostin, S.; Popescu, L.M. A distinct type of cell in myocardium: Interstitial Cajal-like cells (ICLCs). J. Cell 
Mol. Med. 2009,13, 295-308. [CrossRef]
27. Kostin, S. Myocardial telocytes: A specific new cellular entity. J. Cell Mol. Med. 2010, 14, 1917-1921. 
[CrossRef]
28. Kostin, S. Cardiac telocytes in normal and diseased hearts. Semin. Cell Dev. Biol. 2016,55, 22-30. [CrossRef]
29. Aleksandrovych, V.; Pasternak, A.; Basta, P.; Sajewicz, M.; Walocha, J.A.; Gil, K. Telocytes: Facts, speculations 
and myths (Review article). Folia Med. Cracov. 2017, 57, 5-22.
30. Suciu, L.; Nicolescu, M.I.; Popescu, L.M. Cardiac telocytes: Serial dynamic images in cell culture. J. Cell Mol. 
Med. 2010,14, 2687-2692. [CrossRef]
31. Marini, M.; Ibba-Manneschi, L.; Manetti, M. Cardiac Telocyte-Derived Exosomes and Their Possible 
Implications in Cardiovascular Pathophysiology. Adv. Exp. Med. Biol. 2017, 998, 237-254. [PubMed]
32. Bani, D.; Formigli, L.; Gherghiceanu, M.; Faussone-Pellegrini, M.S. Telocytes as supporting cells for myocardial 
tissue organization in developing and adult heart. J. Cell Mol. Med. 2010,14,2531-2538. [CrossRef] [PubMed]
33. Faussone-Pellegrini, M.S.; Bani, D. Relationships between telocytes and cardiomyocytes during pre- and 
post-natal life. J. Cell Mol. Med. 2010,1 4 ,1061-1063. [CrossRef] [PubMed]
34. Zhou, Q.; Wei, L.; Zhong, C.; Fu, S.; Bei, Y.; Huicä, R.I.; Wang, F.; Xiao, J. Cardiac telocytes are double positive 
for CD34/PDGFR-a. J. Cell Mol. Med. 2015,19, 2036-2042. [CrossRef]
35. Yang, Y.; Sun, W.; Wu, S.M.; Xiao, J.; Kong, X. Telocytes in human heart valves. J. Cell Mol. Med. 2014,18, 
759-765. [CrossRef]
36. Chang, Y.; Li, C.; Lu, Z.; Li, H.; Guo, Z. Multiple immunophenotypes of cardiac telocytes. Exp. Cell Res. 2015, 
338, 239-244. [CrossRef]
37. Diaz-Flores, L.; Gutiérrez, R.; Diaz-Flores, L., Jr.; Gonzalez Goméz, M.; Saez, F.J.; Madrid, J.F. Behaviour of 
telocytes during physiopathological activation. Semin. Cell Dev. Biol. 2016, 55,50-61. [CrossRef]
38. Cretoiu, S.M.; Popescu, L.M. Telocytes revisited. Biomol. Concepts. 2014, 5, 353-369. [CrossRef]
39. Matyja, A.; Gil, K.; Pasternak, A.; Sztefko, K.; Gajda, M.; Tomaszewski, K.A.; Matyja, M.; Walocha, J.A.; 
Kulig, J.; Thor, P. Telocytes: New insight into the pathogenesis of gallstone disease. J. Cell Mol. Med. 2013,17, 
734-742. [CrossRef]
40. Aleksandrovych, V.; Walocha, J.A.; Gil, K. Telocytes in female reproductive system (human and animal). 
J. Cell Mol. Med. 2016, 20, 994-1000. [CrossRef]
41. Hutson, H.N.; Marohl, T.; Anderson, M.; Eliceiri, K.; Campagnola, P.; Masters, K.S. Calcific Aortic Valve 
Disease Is Associated with Layer-Specific Alterations in Collagen Architecture. PLoS ONE 2016,11, e0163858. 
[CrossRef] [PubMed]
42. Latif, N.; Sarathchandra, P.; Taylor, P.M.; Antoniw, J.; Yacoub, M.H. Localization and pattern of expression of 
extracellular matrix components in human heart valves. J. Heart Valve Dis. 2005,14, 218-227. [PubMed]
43. Vesely, I. Reconstruction of loads in the fibrosa and ventricularis of porcine aortic valves. ASAIO J. 1996, 42, 
M739-M746. [CrossRef] [PubMed]
44. Blevins, T.L.; Peterson, S.B.; Lee, E.L.; Bailey, A.M.; Frederick, J.D.; Huynh, T.N.; Gupta, V.; Grande-Allen, K.J. 
Mitral valve interstitial cells demonstrate regional, adhesional, and synthetic heterogeneity. Cells Tissues 
Organs 2008,187,113-122. [CrossRef]
45. Simmons, C.A.; Grant, G.R.; Mandachi, E.; Davies, P.F. Spatial heterogeneity of endothelial phenotypes 
correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ. Res. 2005, 96, 
792-799. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 6330 13 of 14
46. Freeman, R.V.; Otto, C.M. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, 
and treatment strategies. Circulation 2005,111, 3316-3326. [CrossRef]
47. Aikawa, E.; Whittaker, P.; Farber, M.; Mendelson, K.; Padera, R.F.; Aikawa, M.; Schoen, F.J. Human semilunar 
cardiac valve remodeling by activated cells from fetus to adult. Circulation 2006,113,1344-1352. [CrossRef]
48. Christie, G.W.; Barratt-Boyes, B.G. Age-dependent changes in the radial stretch of human aortic valve leaflets 
determined by biaxial testing. Ann. Thorac Surg. 1995, 60, S156-S158. [CrossRef]
49. Sell, S.; Scully, R.E. Aging changes in the aortic and mitral valves. Histologic and histochemical studies, 
with observations on the pathogenesis of calcific aortic stenosis and calcification of the mitral annulus. Am. J. 
Pathol. 1965, 46, 345-365. [PubMed]
50. Jian, B.; Narula, N.; Li, Q.Y.; Mohler, E.R., 3rd; Levy, R.J. Progression of aortic valve stenosis: TGF-beta1 is 
present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. 
Ann. Thorac. Surg. 2003, 75, 457-465. [CrossRef]
51. Bonetti, A.; Della Mora, A.; Contin, M.; Gregoraci, G.; Tubaro, F.; Marchini, M.; Ortolani, F. Survival-Related 
Autophagic Activity Versus Procalcific Death in Cultured Aortic Valve Interstitial Cells Treated With Critical 
Normophosphatemic-Like Phosphate Concentrations. J. Histochem. Cytochem. 2017, 6 5 ,125-138. [CrossRef] 
[PubMed]
52. Ortolani, F.; Bonetti, A.; Tubaro, F.; Petrelli, L.; Contin, M.; Nori, S.L.; Spina, M.; Marchini, M. Ultrastructural 
characterization of calcification onset and progression in subdermally implanted aortic valves. Histochemical 
and spectrometric data. Histol Histopathol. 2007, 22, 261-272. [PubMed]
53. Richter, M.; Kostin, S. The failing human heart is characterized by decreased numbers of telocytes as result of 
apoptosis and altered extracellular matrix composition. J. Cell Mol. Med. 2015,19, 2597-2606. [CrossRef] 
[PubMed]
54. Niculite, C.M.; Regalia, T.M.; Gherghiceanu, M.; Huica, R.; Surcel, M.; Ursaciuc, C.; Leabu, M.; Popescu, L.M. 
Dynamics of telopodes (telocyte prolongations) in cell culture depends on extracellular matrix protein. 
Mol. Cell Biochem. 2015, 398,157-164. [CrossRef]
55. Cretoiu, D.; Hummel, E.; Zimmermann, H.; Gherghiceanu, M.; Popescu, L.M. Human cardiac telocytes: 
3D imaging by FIB-SEM tomography. J. Cell Mol. Med. 2014,18, 2157-2164. [CrossRef]
56. Nomura, A.; Seya, K.; Yu, Z.; Daitoku, K.; Motomura, S.; Murakami, M.; Fukuda, I.; Furukawa, K. 
CD34-negative mesenchymal stem-like cells may act as the cellular origin of human aortic valve calcification. 
Biochem. Biophys. Res. Commun. 2013, 440, 780-785. [CrossRef]
57. Hjortnaes, J.; Shapero, K.; Goettsch, C.; Hutcheson, J.D.; Keegan, J.; Kluin, J.; Mayer, J.E.; Bischoff, J.; Aikawa, E. 
Valvular interstitial cells suppress calcification of valvular endothelial cells. Atherosclerosis 2015, 242, 251-260. 
[CrossRef]
58. Schoen, F.J. Evolving concepts of cardiac valve dynamics: The continuum of development, functional 
structure, pathobiology, and tissue engineering. Circulation 2008,118,1864-1880. [CrossRef]
59. Paruchuri, S.; Yang, J.H.; Aikawa, E.; Melero-Martin, J.M.; Khan, Z.A.; Loukogeorgakis, S.; Schoen, F.J.; 
Bischoff, J. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response 
to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ. Res. 2006, 99, 861-869. 
[CrossRef]
60. Biasin, V.; Crnkovic, S.; Sahu-Osen, A.; Birnhuber, A.; El Agha, E.; Sinn, K.; Klepetko, W.; Olschewski, A.; 
Bellusci, S.; Marsh, L.M.; et al. PDGFRa and aSMA mark two distinct mesenchymal cell populations involved 
in parenchymal and vascular remodeling in pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2020, 
318, L684-L697. [CrossRef]
61. Santini, M.P.; Malide, D.; Hoffman, G.; Pandey, G.; D'Escamard, V.; Nomura-Kitabayashi, A.; Rovira, I.; 
Kataoka, H.; Ochando, J.; Harvey, R.P.; et al. Tissue-Resident PDGFRa+ Progenitor Cells Contribute to 
Fibrosis versus Healing in a Context- and Spatiotemporally Dependent Manner. Cell Rep. 2020, 30, 555-570. 
[CrossRef] [PubMed]
62. Zheng, Y.; Cretoiu, D.; Yan, G.; Cretoiu, S.M.; Popescu, L.M.; Fang, H.; Wang, X. Protein profiling of human 
lung telocytes and microvascular endothelial cells using iTRAQ quantitative proteomics. J. Cell Mol. Med. 
2014,1 8 ,1035-1059. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 6330 14 of 14
63. Proudfoot, D.; Skepper, J.N.; Hegyi, L.; Bennett, M.R.; Shanahan, C.M.; Weissberg, P.L. Apoptosis regulates 
human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. 
Circ. Res. 2000, 8 7 ,1055-1062. [CrossRef] [PubMed]
64. Rajamannan, N.M.; Evans, F.J.; Aikawa, E.; Grande-Allen, K.J.; Demer, L.L.; Heistad, D.D.; Simmons, C.A.; 
Masters, K.S.; Mathieu, P.; O'Brien, K.D.; et al. Calcific aortic valve disease: Not simply a degenerative 
process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic 
Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011, 
124,1783-1791. [CrossRef] [PubMed]
©  2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
